ABCL Q3 2021 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-41.2% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$28M-510.1% margin

Net Income

-$21M-388.2% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-80.1%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$15M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$219M

Stockholders' Equity

$953M

Cash & Equivalents

$518M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$9M	-41.2%
Gross Profit	$6M	$9M	-41.2%
Operating Income	-$28M	-$2M	-1489.1%
Net Income	-$21M	-$3M	-693.9%

Revenue Segments

Research Fees

$5M93%

Royalty

$190,0003%

License

$190,0003%